185 related articles for article (PubMed ID: 30056579)
1. Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.
Qiu Y; Zhang CL; Shen KN; Su W; Feng J; Zhang L; Cao XX; Li J
Ann Hematol; 2018 Dec; 97(12):2465-2470. PubMed ID: 30056579
[TBL] [Abstract][Full Text] [Related]
2. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.
Sidana S; Tandon N; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Kyle RA; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Rajkumar SV; Kumar SK
Leukemia; 2018 Mar; 32(3):729-735. PubMed ID: 28919633
[TBL] [Abstract][Full Text] [Related]
3. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome.
Milani P; Basset M; Russo F; Foli A; Merlini G; Palladini G
Blood; 2017 Aug; 130(5):625-631. PubMed ID: 28546143
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.
Nguyen VP; Rosenberg A; Mendelson LM; Comenzo RL; Varga C; Sanchorawala V
Amyloid; 2018 Sep; 25(3):156-159. PubMed ID: 30032640
[TBL] [Abstract][Full Text] [Related]
5. At least partial hematological response after first cycle of treatment predicts organ response and long-term survival for patients with AL amyloidosis receiving bortezomib-based treatment.
Shen KN; Feng J; Huang XF; Zhang CL; Zhang CL; Cao XX; Zhang L; Zhou DB; Li J
Ann Hematol; 2017 Dec; 96(12):2089-2094. PubMed ID: 28956112
[TBL] [Abstract][Full Text] [Related]
6. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.
Dittrich T; Bochtler T; Kimmich C; Becker N; Jauch A; Goldschmidt H; Ho AD; Hegenbart U; Schönland SO
Blood; 2017 Aug; 130(5):632-642. PubMed ID: 28550043
[TBL] [Abstract][Full Text] [Related]
7. [The prognostic value of baseline serum free light chain in immunoglobulin light-chain cardiac amyloidosis].
Wang LM; Wang TT; Tian Y; Zhao L; Yang XC; Chen WM
Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):47-53. PubMed ID: 32023754
[No Abstract] [Full Text] [Related]
8. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.
Sachchithanantham S; Berlanga O; Alvi A; Mahmood SA; Lachmann HJ; Gillmore JD; Hawkins PN; Harding S; Wechalekar AD
Br J Haematol; 2017 Nov; 179(4):575-585. PubMed ID: 28990174
[TBL] [Abstract][Full Text] [Related]
9. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.
Manwani R; Cohen O; Sharpley F; Mahmood S; Sachchithanantham S; Foard D; Lachmann HJ; Quarta C; Fontana M; Gillmore JD; Whelan C; Hawkins PN; Wechalekar AD
Blood; 2019 Dec; 134(25):2271-2280. PubMed ID: 31578202
[TBL] [Abstract][Full Text] [Related]
10. Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio.
Muchtar E; Gertz MA; Lacy MQ; Leung N; Buadi FK; Dingli D; Hayman SR; Go RS; Kapoor P; Gonsalves W; Kourelis TV; Warsame R; Hwa YL; Fonder A; Hobbs M; Russell S; Lust JA; Siddiqui M; Rajkumar SV; Kyle RA; Kumar SK; Dispenzieri A
Am J Hematol; 2020 Nov; 95(11):1280-1287. PubMed ID: 32681737
[TBL] [Abstract][Full Text] [Related]
11. [The prognostic value of baseline serum free light chain in cardiac amyloidosis].
Zhao L; Tian Z; Fang Q
Zhonghua Nei Ke Za Zhi; 2016 Mar; 55(3):186-90. PubMed ID: 26926369
[TBL] [Abstract][Full Text] [Related]
12. Posttreatment dFLC less than 10 mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib.
Shen KN; Miao HL; Zhang CL; Feng J; Zhang L; Cao XX; Zhou DB; Wei S; Li J
Leuk Lymphoma; 2021 Apr; 62(4):874-882. PubMed ID: 33215569
[TBL] [Abstract][Full Text] [Related]
13. Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis.
Sarosiek S; Zheng L; Sloan JM; Quillen K; Brauneis D; Sanchorawala V
Blood Cancer J; 2020 Sep; 10(8):88. PubMed ID: 32873776
[TBL] [Abstract][Full Text] [Related]
14. [Clinical presentation and prognosis in patients with light-chain amyloidosis with an ultra-high level of serum free light-chain].
Miao HL; Shen KN; Su W; Zhang L; Cao XX; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):199-204. PubMed ID: 33910304
[No Abstract] [Full Text] [Related]
15. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.
Rezk T; Lachmann HJ; Fontana M; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Bass P; Hawkins PN; Gillmore JD
Kidney Int; 2017 Dec; 92(6):1476-1483. PubMed ID: 28729034
[TBL] [Abstract][Full Text] [Related]
16. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
[TBL] [Abstract][Full Text] [Related]
17. [The diagnostic and prognostic values of serum free light chain in patients with primary light chain amyloidosis].
Zhang CL; Feng J; Shen KN; Su W; Zhang CL; Huang XF; Cao XX; Zhang L; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):942-945. PubMed ID: 27995877
[TBL] [Abstract][Full Text] [Related]
18. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
[TBL] [Abstract][Full Text] [Related]
19. Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis.
Jimenez-Zepeda VH; Lee H; McCulloch S; Tay J; Duggan P; Neri P; Bahlis N
Amyloid; 2021 Sep; 28(3):182-188. PubMed ID: 34096429
[TBL] [Abstract][Full Text] [Related]
20. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
